株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アブレーション装置:医療機器のパイプライン評価

Ablation Equipments - Medical Devices Pipeline Assessment, 2016

発行 GlobalData 商品コード 346490
出版日 ページ情報 英文 95 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
アブレーション装置:医療機器のパイプライン評価 Ablation Equipments - Medical Devices Pipeline Assessment, 2016
出版日: 2016年04月15日 ページ情報: 英文 95 Pages
概要

当レポートでは、アブレーション装置のパイプライン製品の各開発段階における比較分析などの詳細情報やパイプライン製品の開発に携わっている主な企業 (組織) の概要、現在治験が進行中のパイプライン製品の情報などを提供しています。

第1章 目次

第2章 イントロダクション

  • アブレーション装置の概要

第3章 開発中の製品

  • アブレーション装置 - 開発段階別のパイプライン製品
  • アブレーション装置 - 国 (地域) 別のパイプライン製品
  • アブレーション装置 - 規制別のパイプライン製品
  • アブレーション装置 - 認証時期別 (推定) のパイプライン製品
  • アブレーション装置 - 現在進行中の治験

第4章 アブレーション装置 - 開発中のパイプライン製品:企業別

  • アブレーション装置企業 - 開発段階別のパイプライン製品
  • アブレーション装置 - 開発段階別のパイプライン製品

第5章 アブレーション装置企業と製品の概要

  • AngioDynamics, Inc.の企業概要
    • AngioDynamics, Inc. - パイプライン製品と現在進行中の治験の概要
  • AtriCure, Inc.の企業概要
    • AtriCure, Inc. - パイプライン製品と現在進行中の治験の概要
  • CPSI Biotechの企業概要
    • CPSI Biotech - パイプライン製品と現在進行中の治験の概要
  • EP Global Communications, Inc.の企業概要
    • EP Global Communications, Inc. - パイプライン製品と現在進行中の治験の概要
  • HistoSonics, Inc.の企業概要
    • HistoSonics, Inc. - パイプライン製品と現在進行中の治験の概要
  • Hospital for Special Surgeryの企業概要
    • Hospital for Special Surgery - パイプライン製品と現在進行中の治験の概要
  • Innoblative Designs, Inc.の企業概要
    • Innoblative Designs, Inc. - パイプライン製品と現在進行中の治験の概要
  • Integra LifeSciences Holdings Corporationの企業概要
    • Integra LifeSciences Holdings Corporation - パイプライン製品と現在進行中の治験の概要
  • Intratherm, Llcの企業概要
    • Intratherm, Llc - パイプライン製品と現在進行中の治験の概要
  • Medtronic plcの企業概要
    • Medtronic plc - パイプライン製品と現在進行中の治験の概要
  • Mirabilis Medica, Inc.の企業概要
    • Mirabilis Medica, Inc. - パイプライン製品と現在進行中の治験の概要
  • Northwestern Universityの企業概要
    • Northwestern University - パイプライン製品と現在進行中の治験の概要
  • Prosurg, Inc.の企業概要
    • Prosurg, Inc. - パイプライン製品と現在進行中の治験の概要
  • Sanarus Technologies, LLCの企業概要
    • Sanarus Technologies, LLC - パイプライン製品と現在進行中の治験の概要
  • Smith & Nephew Plcの企業概要
    • Smith & Nephew Plc - パイプライン製品と現在進行中の治験の概要
  • Thermedical, Inc.の企業概要
    • Thermedical, Inc. - パイプライン製品と現在進行中の治験の概要
  • TransEnterix, Inc.の企業概要
    • TransEnterix, Inc. - パイプライン製品と現在進行中の治験の概要
  • University of California, San Franciscoの企業概要
    • University of California, San Francisco - パイプライン製品と現在進行中の治験の概要
  • University of Texas at Austinの企業概要
    • University of Texas at Austin - パイプライン製品と現在進行中の治験の概要
  • University of Wisconsin-Stoutの企業概要
    • University of Wisconsin-Stout - パイプライン製品と現在進行中の治験の概要

第6章 アブレーション装置 - 最近の動向

第7章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDME0150EPD

GlobalData's Medical Devices sector report, "Ablation Equipments - Medical Devices Pipeline Assessment, 2016" provides an overview of Ablation Equipments currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Ablation Equipments pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Ablation Equipments under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Ablation Equipments and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Ablation Equipments under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Ablation Equipments Overview

3. Products under Development

  • 3.1. Ablation Equipments. Pipeline Products by Stage of Development
  • 3.2. Ablation Equipments. Pipeline Products by Territory
  • 3.3. Ablation Equipments. Pipeline Products by Regulatory Path
  • 3.4. Ablation Equipments. Pipeline Products by Estimated Approval Date
  • 3.5. Ablation Equipments. Ongoing Clinical Trials

4. Ablation Equipments. Pipeline Products under Development by Companies

  • 4.1. Ablation Equipments Companies. Pipeline Products by Stage of Development
  • 4.2. Ablation Equipments. Pipeline Products by Stage of Development

5. Ablation Equipments Companies and Product Overview

  • 5.1. AngioDynamics, Inc. Company Overview
    • 5.1.1. AngioDynamics, Inc. Pipeline Products. Ongoing Clinical Trials Overview
  • 5.2. AtriCure, Inc. Company Overview
    • 5.2.1. AtriCure, Inc. Pipeline Products. Ongoing Clinical Trials Overview
  • 5.3. CPSI Biotech Company Overview
    • 5.3.1. CPSI Biotech Pipeline Products. Ongoing Clinical Trials Overview
  • 5.4. EP Global Communications, Inc. Company Overview
    • 5.4.1. EP Global Communications, Inc. Pipeline Products. Ongoing Clinical Trials Overview
  • 5.5. HistoSonics, Inc. Company Overview
    • 5.5.1. HistoSonics, Inc. Pipeline Products. Ongoing Clinical Trials Overview
  • 5.6. Hospital for Special Surgery Company Overview
    • 5.6.1. Hospital for Special Surgery Pipeline Products. Ongoing Clinical Trials Overview
  • 5.7. Innoblative Designs, Inc. Company Overview
    • 5.7.1. Innoblative Designs, Inc. Pipeline Products. Ongoing Clinical Trials Overview
  • 5.8. Integra LifeSciences Holdings Corporation Company Overview
    • 5.8.1. Integra LifeSciences Holdings Corporation Pipeline Products. Ongoing Clinical Trials Overview
  • 5.9. Intratherm, Llc Company Overview
    • 5.9.1. Intratherm, Llc Pipeline Products. Ongoing Clinical Trials Overview
  • 5.10. Medtronic plc Company Overview
    • 5.10.1. Medtronic plc Pipeline Products. Ongoing Clinical Trials Overview
  • 5.11. Memorial Sloan Kettering Cancer Center Company Overview
    • 5.11.1. Memorial Sloan Kettering Cancer Center Pipeline Products. Ongoing Clinical Trials Overview
  • 5.12. Mirabilis Medical, Inc. Company Overview
    • 5.12.1. Mirabilis Medical, Inc. Pipeline Products. Ongoing Clinical Trials Overview
  • 5.13. Prosurg, Inc. Company Overview
    • 5.13.1. Prosurg, Inc. Pipeline Products. Ongoing Clinical Trials Overview
  • 5.14. Smith. Nephew Plc Company Overview
    • 5.14.1. Smith. Nephew Plc Pipeline Products. Ongoing Clinical Trials Overview
  • 5.15. Thermedical, Inc. Company Overview
    • 5.15.1. Thermedical, Inc. Pipeline Products. Ongoing Clinical Trials Overview
  • 5.16. TransEnterix, Inc. Company Overview
    • 5.16.1. TransEnterix, Inc. Pipeline Products. Ongoing Clinical Trials Overview
  • 5.17. University of California, San Francisco Company Overview
    • 5.17.1. University of California, San Francisco Pipeline Products. Ongoing Clinical Trials Overview
  • 5.18. University of Texas at Austin Company Overview
    • 5.18.1. University of Texas at Austin Pipeline Products. Ongoing Clinical Trials Overview
  • 5.19. University of Wisconsin-Stout Company Overview
    • 5.19.1. University of Wisconsin-Stout Pipeline Products. Ongoing Clinical Trials Overview

6. Ablation Equipments- Recent Developments

  • 6.1. Mar 22, 2016: Kim Bridges joins Halt Medical as President and Chief Executive Officer
  • 6.2. Mar 21, 2016: CSA Medical Announces the First Presentation of the RejuvenAir System Metered Cryospray Clinical Data
  • 6.3. Feb 25, 2016: Integra LifeSciences Reports Fourth Quarter and Full Year 2015 Financial Results and Issues 2016 Full Year Guidance
  • 6.4. Feb 25, 2016: Integra LifeSciences Announces Service Alliance Agreement With PREZIO Health
  • 6.5. Feb 09, 2016: Misonix Announces Second Quarter Fiscal Year 2016 Financial Results
  • 6.6. Jan 13, 2016: Medtronic Expands Pain Therapies Portfolio with the Launch of OsteoCool RF Ablation System
  • 6.7. Dec 22, 2015: Galil Medical Terminates Acquisition of Perseon for up to USD10.6 Million
  • 6.8. Dec 18, 2015: Relievant Medsystems Raises USD1.5 Million in Venture Financing
  • 6.9. Dec 16, 2015: Medtronic Acquires OsteoCool RF Ablation System from Baylis Medical
  • 6.10. Dec 15, 2015: DFINE Announces Commercial Launch of the Long SpineSTAR Ablation Instrument for the Palliative Treatment of Metastatic Spine Tumors
  • 6.11. Nov 26, 2015: Google Files For Patent For Laser Ablation Surgical System
  • 6.12. Nov 10, 2015: C2 Therapeutics Announces New Data Confirming Efficacy and Safety of Coldplay CryoBalloon Focal Ablation System to Treat Esophageal Disease
  • 6.13. Nov 05, 2015: Misonix Announces First Quarter Fiscal Year 2016 Financial Results
  • 6.14. Nov 03, 2015: Integra LifeSciences Reports Third Quarter 2015 Financial Results
  • 6.15. Oct 30, 2015: Integra LifeSciences Receives Expanded Indication for CUSA Excel+ System for Liver Surgery
  • 6.16. Oct 15, 2015: AngioDynamics Announces the Approval of the NanoKnife System in South Korea
  • 6.17. Sep 15, 2015: Perseon Announces New Data for MicroThermX in the Treatment of Large Liver Metastases From Colorectal Cancer and Large Hepatocellular Carcinoma From 2015. SICO Conference
  • 6.18. Aug 31, 2015: Perseon Announces the Initiation of the First Multi-Organ in vivo Ablation Zone Study for MicroThermX in Laparoscopic and Open Approaches
  • 6.19. Aug 31, 2015: Integra LifeSciences Raises USD220 Million in Public Offering of Shares
  • 6.20. Aug 20, 2015: Misonix Announces Fourth Quarter And Fiscal Year End 2015 Financial Results
  • 6.21. Aug 19, 2015: Perseon Launches INSPIRE 2017,. Dramatic Effort to Increase Adoption of Microwave Ablation to Fight Cancer
  • 6.22. Aug 13, 2015: Research Data Published in Annals of Surgery Concludes Irreversible Electroporation Utilizing NanoKnife Results in Substantially Prolonged Survival for Patients With Locally Advanced Pancreatic Cancer Compared With Historical Controls
  • 6.23. Aug 06, 2015: Perseon Announces Data Presented at the American Association of Physicists in Medicine Meeting Supporting the Use of Microwave Ablation
  • 6.24. Aug 04, 2015: Perseon Announces. User Enhancement Upgrade for Energy Ablation System MicroThermX
  • 6.25. Aug 04, 2015: Integra LifeSciences Prices Public Offering of Shares for USD201.3 Million
  • 6.26. Jul 30, 2015: Integra LifeSciences Reports Second Quarter 2015 Financial Results
  • 6.27. Jul 29, 2015: C2 Therapeutics Receives FDA 510(k) Clearance for the Coldplay Full CryoBalloon Ablation System
  • 6.28. Jul 29, 2015: C2 Therapeutics Receives FDA 510(k) Clearance for the Coldplay Swipe CryoBalloon Ablation System
  • 6.29. Jul 20, 2015: C2 Therapeutics Announces Successful Safety and Dosing Results of Coldplay Cryoballoon Focal Ablation System in International Trial
  • 6.30. Jul 16, 2015: Cianna Medical Raises USD4 Million in Venture Financing Round
  • 6.31. Jul 09, 2015: SonaCare Medical Sells Prostate Ablation System with MRI/Ultrasound Image Fusion to Heidelberg Prostate Clinic
  • 6.32. Jul 01, 2015: Integra LifeSciences Completes Spin-Off of SeaSpine
  • 6.33. May 18, 2015: CSA Medical Announces Publication of Results of National Cryospray Registry in Diseases of the Esophagus
  • 6.34. May 07, 2015: Misonix Announces Third Quarter Fiscal Year 2015 Financial Results
  • 6.35. May 06, 2015: Perseon's MicroThermX to be Featured at WCIO 2015 Interventional Oncology Forum
  • 6.36. May 06, 2015: NeuWave Medical Raises USD25 Million in Series. Financing
  • 6.37. Apr 30, 2015: Integra LifeSciences Names Keith Valentine as Chief Executive Officer of SeaSpine; John Bostjancic Appointed as Chief Financial Officer of SeaSpine
  • 6.38. Apr 30, 2015: Integra LifeSciences Reports First Quarter 2015 Financial Results
  • 6.39. Apr 24, 2015: New Data Shows Irreversible Electroporation Nearly Doubles Overall Survival of Patients with Locally Advanced Pancreatic Cancer When Added to Standard Therapy
  • 6.40. Apr 14, 2015: Perseon Announces FDA Clearance for Specific Indication of Non-Resectable Liver Tumor Ablation

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Ablation Equipments - Pipeline Products by Stage of Development
  • Table 2: Ablation Equipments - Pipeline Products by Territory
  • Table 3: Ablation Equipments - Pipeline Products by Regulatory Path
  • Table 4: Ablation Equipments - Pipeline Products by Estimated Approval Date
  • Table 5: Ablation Equipments - Ongoing Clinical Trials
  • Table 6: Ablation Equipments Companies - Pipeline Products by Stage of Development
  • Table 7: Ablation Equipments - Pipeline Products by Stage of Development
  • Table 8: AngioDynamics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Status
  • Table 10: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Description
  • Table 11: NanoKnife System - Pancreatic Cancer - Product Status
  • Table 12: NanoKnife System - Pancreatic Cancer - Product Description
  • Table 13: NanoKnife System - Prostate Cancer - Product Status
  • Table 14: NanoKnife System - Prostate Cancer - Product Description
  • Table 15: Next Generation Microwave Ablation - Product Status
  • Table 16: Next Generation Microwave Ablation - Product Description
  • Table 17: Next Generation NanoKnife Device - Product Status
  • Table 18: Next Generation NanoKnife Device - Product Description
  • Table 19: AngioDynamics, Inc. - Ongoing Clinical Trials Overview
  • Table 20: NanoKnife System - Prostate Cancer - A Prospective Development Study Evaluating Focal Therapy Using Irreversible Electroporation (Nanoknife) in Men with Localised Prostate Cancer
  • Table 21: NanoKnife System - Prostate Cancer - Irreversible Electroporation(IRE) for Unresectable Prostatic Neoplasms: Phase I and Phase II Clinical Trial
  • Table 22: NanoKnife System - Prostate Cancer - Multi-center Randomized Clinical Two Arm Intervention Study Evaluating Irreversible Electroporation for the Ablation of Localized Prostate Cancer
  • Table 23: NanoKnife System - Pancreatic Cancer - Evaluation of the Short and Intermediate Term Outcomes of Ablation of Locally Advanced Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System - A Prospective Study
  • Table 24: NanoKnife System - Pancreatic Cancer - IRE: Anti-tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer
  • Table 25: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - A Prospective Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Unresectable Hepatic Carcinoma Close to the Gallbladder
  • Table 26: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Colorectal Metastatic Liver Disease: Efficacy of Irreversible Electroporation (IRE) - A Phase II Clinical Trial (COLDFIRE-2 Study)
  • Table 27: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Comparison Percutaneous Cryosurgery and Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome
  • Table 28: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Hepatic Carcinoma in Poor Liver Function: Safety and Efficacy of Irreversible Electroporation (IRE)
  • Table 29: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Irreversible Electroporation (IRE) for Unresectable Portal Venous Tumor Emboli: Phase I and Phase II Clinical Trial
  • Table 30: AtriCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 31: COBRA Revolution Bipolar Clamp - Product Status
  • Table 32: COBRA Revolution Bipolar Clamp - Product Description
  • Table 33: CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview
  • Table 34: Pressurized Sub-Cooled Nitrogen System - Product Status
  • Table 35: Pressurized Sub-Cooled Nitrogen System - Product Description
  • Table 36: Super-Critical Nitrogen (SCN) Cryoablation Platform - Product Status
  • Table 37: Super-Critical Nitrogen (SCN) Cryoablation Platform - Product Description
  • Table 38: EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 39: MEMS Nerve Ablation Device - Back Pain - Product Status
  • Table 40: MEMS Nerve Ablation Device - Back Pain - Product Description
  • Table 41: MEMS Nerve Ablation Device - Facial Glabballar Frowning - Product Status
  • Table 42: MEMS Nerve Ablation Device - Facial Glabballar Frowning - Product Description
  • Table 43: HistoSonics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 44: Vortx RX - Product Status
  • Table 45: Vortx RX - Product Description
  • Table 46: HistoSonics, Inc. - Ongoing Clinical Trials Overview
  • Table 47: Vortx RX - Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)
  • Table 48: Hospital for Special Surgery Pipeline Products & Ongoing Clinical Trials Overview
  • Table 49: Radiofrequency Ablation Device - Product Status
  • Table 50: Radiofrequency Ablation Device - Product Description
  • Table 51: Innoblative Designs, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 52: RFA Applicator - Product Status
  • Table 53: RFA Applicator - Product Description
  • Table 54: Innoblative Designs, Inc. - Ongoing Clinical Trials Overview
  • Table 55: RFA Applicator - Feasibility Study of Cavitary Radiofrequency Ablation in Excised Mastectomy Breast Tissue
  • Table 56: Integra LifeSciences Holdings Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 57: CUSA Ultrasonic Tissue Ablation System - Liver - Product Status
  • Table 58: CUSA Ultrasonic Tissue Ablation System - Liver - Product Description
  • Table 59: Intratherm, Llc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 60: CITT Device - Product Status
  • Table 61: CITT Device - Product Description
  • Table 62: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 63: Barrx 360 Express - Product Status
  • Table 64: Barrx 360 Express - Product Description
  • Table 65: Electrosurgical Ablation Device - Product Status
  • Table 66: Electrosurgical Ablation Device - Product Description
  • Table 67: Nerve Cryoablation System - Product Status
  • Table 68: Nerve Cryoablation System - Product Description
  • Table 69: OsteoCool V-2 RF Ablation System - Product Status
  • Table 70: OsteoCool V-2 RF Ablation System - Product Description
  • Table 71: Phased RF Ablation System - Product Status
  • Table 72: Phased RF Ablation System - Product Description
  • Table 73: Medtronic plc - Ongoing Clinical Trials Overview
  • Table 74: Phased RF Ablation System - Evaluation of Multielectrode Phased RF Technology in Persistent Atrial Fibrillation
  • Table 75: Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview
  • Table 76: Image-Guided Ablation Device - Product Status
  • Table 77: Image-Guided Ablation Device - Product Description
  • Table 78: Mirabilis Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 79: Mirabilis System - Product Status
  • Table 80: Mirabilis System - Product Description
  • Table 81: Prosurg, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 82: ImaGel - Product Status
  • Table 83: ImaGel - Product Description
  • Table 84: Smith & Nephew Plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 85: Next-Generation COBLATION Platform - Product Status
  • Table 86: Next-Generation COBLATION Platform - Product Description
  • Table 87: Thermedical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 88: SERF Ablation System - Fibroids - Product Status
  • Table 89: SERF Ablation System - Fibroids - Product Description
  • Table 90: TransEnterix, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 91: Barrett's Excision Device - Product Status
  • Table 92: Barrett's Excision Device - Product Description
  • Table 93: University of California, San Francisco Pipeline Products & Ongoing Clinical Trials Overview
  • Table 94: Robotic Needle Ablation Tool And Securement Device - Product Status
  • Table 95: Robotic Needle Ablation Tool And Securement Device - Product Description
  • Table 96: University of Texas at Austin Pipeline Products & Ongoing Clinical Trials Overview
  • Table 97: Plasmonic Laser Ablation Device - Product Status
  • Table 98: Plasmonic Laser Ablation Device - Product Description
  • Table 99: University of Wisconsin-Stout Pipeline Products & Ongoing Clinical Trials Overview
  • Table 100: Microwave Ablation Probe - Product Status
  • Table 101: Microwave Ablation Probe - Product Description
  • Table 102: Glossary

List of Figures

  • Figure 1: Ablation Equipments - Pipeline Products by Stage of Development
  • Figure 2: Ablation Equipments - Pipeline Products by Territory
  • Figure 3: Ablation Equipments - Pipeline Products by Regulatory Path
  • Figure 4: Ablation Equipments - Pipeline Products by Estimated Approval Date
  • Figure 5: Ablation Equipments - Ongoing Clinical Trials
Back to Top